Business Wire

American Airlines Pilots First to Use CEFA Aviation Flight Replay App in the U.S.

7.12.2021 13:16:00 EET | Business Wire | Press release

Share

American Airlines, the world’s largest airline, is the first carrier in the U.S. to adopt CEFA AMS, an Electronic Flight Bag (EFB) application allowing pilots to virtually review flight data on their tablet after landing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005055/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing. (Photo: Business Wire)

CEFA AMS (Aviation Mobile Services) is the first self-improvement tool allowing individual pilots to access and review the specifics of their flight after landing.

Captain Neil Raaz, Operations Safety Director at American Airlines, says that CEFA AMS is the next step in American’s data-driven approach to relentlessly advance safety. “By choosing CEFA AMS, we are now able to advance the Safety-II approach in a practical way in our operations. This progressive new debriefing capability will help promote a culture of continuous self-improvement and reinforce American’s safety-first mentality into each and every flight.”

“We are delighted to partner with American Airlines, who sets the standard when it comes to flight safety,” says Dominique Mineo, CEO of CEFA Aviation , a France-based software company specialized in flight safety and pilot training. “Being able to deploy our innovation in the U.S. was one of our main ambitions. Today we have the opportunity to work with an airline committed to the highest safety standards and, beyond the conventional safety approach, aiming for Safety-II implementation.” Mineo added.

The implementation of CEFA Aviation’s EFB flight replay capability is a milestone for American. It demonstrates its will for innovation as well as a strong desire to lead the shift in pilot empowerment through increased access to and awareness of operational flight data.

This new partnership between CEFA and American Airlines will create an entirely new and revolutionary approach to proactive safety in airline operations and clearly demonstrates both organization’s commitment to being industry leaders in aviation safety.

About CEFA Aviation

CEFA Aviation, a privately held French company, enhances pilot training and flight safety, developing world-leading 3D animation software and services for the past 20 years. The innovative solutions developed by its experts recreate flights with high details and accuracy based on data from aircraft flight recorders.

More than 100 major and regional airlines, cargo operators, and investigative authorities on five continents are using the company’s core software, CEFA FAS (Flight Animation System), for pilot training and safety analysis.

Translating flight data into precise visualization requires an in-depth understanding of the complexity of aircraft systems and software engineering. CEFA Aviation has been a pioneer in easy-to-use flight data animation since Dominique Mineo founded the company in 2000. Its long-lasting success is attributable to a passion for aviation and innovation, listening to its clients, and delivering gold-standard support. CEFA Aviation is headquartered in the Alsace region of France.

At the Dubai Airshow 2017, CEFA Aviation unveiled a new breakthrough visualization tool to enhance further and personalize pilot training: CEFA AMS. Additional information can be found at www.cefa-aviation.com

Join us on social media and never miss a press release on Twitter @CEFAAviation and LinkedIn at www.linkedin.com/company/cefa-aviation

About American Airlines Group

American’s purpose is to care for people on life’s journey. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the company’s stock is included in the S&P 500. Learn more about what’s happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CEFA Aviation
Paulina Calderon
communication@cefa-aviation.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye